Clene Awarded Grant From National Multiple Sclerosis Society To Advance Development Of CNM-Au8 In Non-Active Progressive Multiple Sclerosis
Portfolio Pulse from Happy Mohamed
Clene, Inc. (NASDAQ:CLNN) has been awarded a grant from the National Multiple Sclerosis Society (NMSS) to advance the development of its lead drug candidate, CNM-Au8, in non-active progressive multiple sclerosis. The grant will fund Cohort 2 of the REPAIR-MS Phase 2 clinical study, which aims to determine the effects of CNM-Au8 on brain energy metabolites in patients with non-active progressive MS.
May 25, 2023 | 12:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Clene, Inc. has received a grant from the NMSS to advance the development of CNM-Au8 in non-active progressive multiple sclerosis, potentially boosting its stock price.
The grant from the NMSS will help Clene, Inc. advance the development of its lead drug candidate, CNM-Au8, in non-active progressive multiple sclerosis. This could lead to positive results in the Phase 2 clinical study, which would increase the potential value of the drug and, in turn, boost the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100